       Document 0908
 DOCN  M95A0908
 TI    Principles for adoptive T cell therapy of human viral diseases.
 DT    9510
 AU    Riddell SR; Greenberg PD; Program in Immunology, Fred Hutchinson Cancer
       Research Center,; Seattle, Washington 98104, USA.
 SO    Annu Rev Immunol. 1995;13:545-86. Unique Identifier : AIDSLINE
       MED/95336690
 AB    The development of successful adoptive immunotherapy for human virus
       infections is predicated on an understanding of the effector cells and
       mechanisms essential for providing the host with a protective response
       to acute infection and the requirements for long-term in vivo survival
       of transferred cells that will be necessary to provide memory responses
       to persistent and latent viral infections. In this review, we discuss
       the results of recent studies examining the effector mechanisms mediated
       by virus-specific alpha beta + T cells and the strategies viruses have
       evolved to evade recognition by such T cells and/or to interfere with
       the expression of T cell effector functions. The evasion strategies
       employed by individual viruses can render T cell subsets or T cells of
       particular specificities less effective in eliminating virally infected
       cells, and consequently they are less desirable choices for use in
       adoptive therapy. Insights derived from described studies of the
       pathogenesis and immunobiology of virus infections have resulted in the
       development of clinical adoptive immunotherapy studies for infections
       with CMV, EBV, and HIV. Although the results from such studies are
       preliminary, the principle that virus-specific T cells can be
       successfully transferred and can mediate therapeutic efficacy in humans
       has already been affirmed. The use of recently developed methods, such
       as retroviral-mediated gene transfer, to genetically modify
       antigen-specific T cell clones provides a novel approach to overcome
       limitations and improve on the safety and efficacy observed in these
       initial studies, suggesting that more widespread use of adoptive
       transfer of specific T cells as a therapeutic regimen should be feasible
       in the near future.
 DE    Animal  Cytomegalovirus Infections/IMMUNOLOGY/THERAPY  CD4-Positive
       T-Lymphocytes/IMMUNOLOGY  CD8-Positive T-Lymphocytes/IMMUNOLOGY
       Herpesviridae Infections/IMMUNOLOGY/THERAPY  Herpesvirus 4, Human  Human
       HIV Infections/IMMUNOLOGY/THERAPY  HIV-1  Immunologic Memory
       *Immunotherapy, Adoptive  Mice  Receptors, Antigen, T-Cell,
       alpha-beta/METABOLISM  Support, Non-U.S. Gov't  Support, U.S. Gov't,
       P.H.S.  T-Lymphocyte Subsets/IMMUNOLOGY  T-Lymphocytes/*IMMUNOLOGY
       Tumor Virus Infections/IMMUNOLOGY/THERAPY  Virus
       Diseases/IMMUNOLOGY/*THERAPY  JOURNAL ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

